Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study -- Friedberg et al. 26 (2): 204 -- Journal of Clinical Oncology
Links shared publicly online about this topic.
- 1,713total visits
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study -- Friedberg et al. 26 (2): 204 -- Journal of Clinical Oncology
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study -- Friedberg et al. 26 (2): 204 -- Journal of Clinical Oncology
View full resource at jco.ascopubs.org
Tags: Cancer, Lymphoma, Non-Hodgkin Lymphoma, Drug, Oncology
Most Recently Shared on September 29, 2009 at 4:10 pm By:
Emerging treatments for indolent lymphoma http://bit.ly/17omZT Bendamustine, investigational drug: http://bit.ly/N8BqO
Advertisement
